GlassScriptPhysician profile
Indira C Misra Higgins
NPI 1366426454
$4,972.46
in general payments reported to CMS, 2019-2025
36 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $346 · 2021: $772 · 2022: $698 · 2023: $577 · 2024: $899 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,701 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.40 |
| Education | $184.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $996.77 | 2020-2025 | Tremfya |
| Pfizer INC. | $457.32 | 2019-2025 | |
| Journey Medical Corporation | $352.55 | 2021-2025 | |
| Abbvie INC. | $274.18 | 2019-2025 | |
| Ucb, INC. | $263.16 | 2022-2025 | Bimzelx |
| Amgen INC. | $241.79 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $239.26 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $234.11 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $198.91 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $189.31 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $171.68 | 2020-2024 | Jublia, Cabtreo |
| Dermavant Sciences, INC. | $166.44 | 2023-2024 | Vtama |
| Organon LLC | $150.79 | 2025 | Vtama |
| Almirall LLC | $97.11 | 2024-2025 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $91.08 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $90.33 | 2020-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $89.38 | 2021-2022 | |
| Epi Health, LLC | $71.65 | 2019-2022 | |
| Lilly USA, LLC | $65.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $58.03 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.85 | 2023-2024 | Sotyktu |
| Dermira, INC. | $53.79 | 2019-2021 | |
| Incyte Corporation | $45.66 | 2022-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $45.47 | 2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $42.01 | 2024-2025 | Clear+Brilliant |
| Organogenesis INC. | $36.46 | 2024 | |
| Encore Dermatology INC. | $33.49 | 2019 | |
| Janssen Scientific Affairs, LLC | $32.87 | 2021 | |
| Allergan, INC. | $29.07 | 2019-2021 | |
| Cipher Pharmaceuticals US LLC | $24.43 | 2025 | Spinosad, Natroba |
| Botanix Sb INC | $22.69 | 2025 | Sofdra |
| Mission Pharmacal Company | $14.72 | 2019 | |
| Lnhc, INC | $13.99 | 2025 | Zelsuvmi |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Biofrontera INC. | $7.79 | 2019 | |
| Prugen, INC. Pharmaceuticals | $3.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Misra Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.